Cell Therapy Takes Aim at Rare Nerve Tumors in New Preclinical Breakthrough

For patients with neurofibromatosis type 1 (NF1) and schwannomatosis (SWN), the tumors that grow along their nerves have long been among the most stubborn targets in oncology. Surgical resection remains the mainstay of care, but complete removal is often impossible when tumors wrap around critical nerves and spinal structures, and no approved drug has yet delivered a reliable, durable response for the most dangerous form of these growths, the malignant peripheral nerve sheath tumor, or MPNST. Now a team of researchers in Beijing has reported the first preclinical proof of concept that tumor-infiltrating lymphocyte (TIL) therapy, an approach that has already produced remarkable remissions in melanoma and is advancing in other solid cancers, can be adapted to these hereditary nerve sheath tumors. Writing in Cancer Immunology, Immunotherapy, the group describes both the biological rationale and a refined manufacturing protocol that could carry the treatment into human trials.

The logic of TIL therapy rests on a simple observation: many tumors are not immunological deserts. Immune cells, particularly T lymphocytes, physically penetrate tumor tissue, where they can recognize mutated or aberrantly expressed proteins and kill the malignant cells they encounter. The therapeutic strategy involves harvesting a piece of the patient’s tumor, isolating the lymphocytes trapped inside, expanding them to billions of cells in the laboratory, and then reinfusing this amplified army back into the patient, usually after lymphodepleting chemotherapy creates immunological space. The approach has produced durable complete responses in a substantial fraction of advanced melanoma patients and is being tested in cervical cancer, lung cancer, and sarcomas. Whether it could work in NF1- and SWN-related tumors, however, had never been systematically examined, leaving a significant gap for a patient population with few options.

The first question the researchers addressed was whether these tumors actually harbor the T cell infiltrates that TIL therapy requires. They examined 109 clinical specimens spanning the disease spectrum, including benign neurofibromas from NF1 patients, schwannomas from SWN patients, and MPNSTs. Using immunohistochemistry to detect the pan-T cell marker CD3, they found moderate to high T cell infiltration in the overwhelming majority of samples: 84.0 percent of neurofibromas, 98.3 percent of schwannomas, and 75.0 percent of MPNSTs. This was a critical finding, because it established the biological prerequisite for the therapy. If the tumors had been largely devoid of T cells, harvesting and expanding meaningful numbers of tumor-reactive lymphocytes would have been futile. Instead, the data suggested that immune cells are already trafficking into these lesions in most patients, presumably drawn by tumor-associated antigens.

With the rationale established, the team turned to the practical challenge of growing these cells outside the body. Traditional TIL manufacturing relies on high-dose interleukin-2 (IL-2), a potent growth factor that drives T cell proliferation but can also skew the resulting cell population, exhaust the cells, and lengthen production times. The researchers developed an alternative protocol, designated OM-400, that combines stimulation through CD3 and CD28, the two key signaling receptors on T cells, using antibody-coated beads, with a much lower dose of IL-2 at 400 international units per milliliter. The CD3/CD28 co-stimulation mimics the two signals a T cell normally receives when it recognizes its target, providing activation in a more physiological manner than flooding the culture with cytokine alone.

The results of the head-to-head comparison were striking. OM-400 achieved successful expansion in 100 percent of the TIL cultures derived from NF1/SWN-related nerve sheath tumors, whereas the traditional high-dose IL-2 method did not consistently reach that benchmark. The new protocol also shortened the time required to grow the cells to therapeutic numbers, an important consideration for patients with aggressive MPNSTs who cannot afford to wait weeks for a product. Flow cytometric analysis showed that OM-400 cultures were enriched for CD8-positive effector T cells, the cytotoxic subset responsible for directly killing tumor cells. In an analysis of one representative specimen, the protocol also showed preliminary evidence of better preservation of the original T cell receptor (TCR) repertoire, meaning the diverse array of antigen-recognition specificities present in the patient’s tumor was maintained through the expansion process rather than being narrowed by overgrowth of a few clones.

Functionally, the OM-400-expanded cells proved more potent. When co-cultured with autologous tumor cells, meaning tumor cells taken from the same patient whose lymphocytes were being expanded, the cells produced under the new protocol showed enhanced tumor-reactive cytotoxicity, killing more cancer cells than their conventionally grown counterparts. They also secreted higher levels of interferon-gamma (IFN-γ), a signature inflammatory cytokine released when T cells genuinely recognize their targets. Together, these assays indicated that the OM-400 product was not merely larger in number but qualitatively better: more cytotoxic, more tumor-reactive, and more faithful to the immune landscape of the original tumor.

An important exploratory analysis examined whether the type of tumor influenced TIL performance. The team compared results across 15 independent patient samples covering NF1-related neurofibromas, SWN-related schwannomas, and NF1-related MPNSTs. No statistically significant differences emerged among the subtypes, suggesting that a single manufacturing platform might serve the entire disease spectrum. The authors are careful to note, however, that the study was not powered to establish equivalence, and larger cohorts will be needed to definitively assess whether tumor subtype affects TIL yield, phenotype, or reactivity. This caveat reflects the rarity of these conditions; collecting large numbers of fresh surgical specimens from NF1 and SWN patients is inherently difficult, making the 15-sample dataset a meaningful start rather than a final answer.

The decisive test came in animal models. The researchers used patient-derived xenografts (PDX), in which fragments of an MPNST patient’s tumor are implanted into immunodeficient mice, preserving the molecular characteristics of the original cancer. When OM-400-expanded TILs were delivered to these tumor-bearing mice, the cells successfully infiltrated the tumor tissue, a nontrivial requirement since many cell therapies fail because they cannot physically reach and penetrate the tumor mass. More importantly, the treated animals showed significant suppression of tumor growth compared with controls. This in vivo efficacy demonstrated that the laboratory-manufactured cells retained their killing capacity in a living biological system, not just in a culture dish, and provided the strongest evidence yet that the approach could translate to patients.

The significance of the work extends beyond a single protocol. NF1 affects approximately one in 2,500 to 3,000 births worldwide, and while most neurofibromas are benign, they can cause disfigurement, pain, and neurological deficits, and a subset progresses to life-threatening MPNSTs, for which five-year survival remains poor even with aggressive surgery, radiation, and chemotherapy. Recent years have seen encouraging but limited progress with targeted agents such as MEK inhibitors for inoperable plexiform neurofibromas, yet MPNST has remained essentially untouched by systemic therapy. A cellular immunotherapy platform that works across the NF1/SWN tumor spectrum would represent an entirely new therapeutic modality for these patients, and one that could in principle be personalized to each individual’s tumor.

Considerable work remains before the first patient receives an infusion. The study is preclinical, and the transition from PDX mice to human trials will require regulatory-grade manufacturing, safety testing, and careful attention to questions the current data cannot answer, such as the durability of responses, the optimal lymphodepletion regimen, and whether the TCR repertoire preservation seen in a single representative specimen holds broadly. The authors emphasize that their contribution is a reproducible manufacturing platform and a proof of biological feasibility, the foundations on which clinical translation can now be built. For a community of patients who have watched decades of research yield few new options, the demonstration that their tumors are infiltrated by T cells that can be grown, armed, and sent back to fight is a milestone worth noting, and one that turns a long-standing immunological question into a concrete path toward the clinic.

Subject of Research: Tumor-infiltrating lymphocyte immunotherapy for NF1/SWN-related nerve sheath tumors

Article Title: Development of TIL therapy for NF1/SWN-related nerve sheath tumors

Article References: Development of TIL therapy for NF1/SWN-related nerve sheath tumors. (n.d.). https://doi.org/10.1007/s00262-026-04595-6

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04595-6

Keywords: TIL therapy, NF1, schwannomatosis, MPNST, adoptive cell therapy, immunotherapy, patient-derived xenograft, CD8 T cells, interleukin-2, TCR repertoire, nerve sheath tumors, preclinical study